A Pilot Phase II Study of Erlotinib for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Trial Profile

A Pilot Phase II Study of Erlotinib for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Jun 2017 Planned primary completion date changed from 1 May 2018 to 1 May 2019.
    • 15 Jun 2016 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
    • 09 Jun 2015 Planned primary completion date changed from 1 May 2016 to 1 May 2017 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top